Scinai Immunotherapeutics Ltd.
SCNI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001611747
No open-market purchases or sales by Scinai Immunotherapeutics Ltd. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $49.1K in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Scinai Immunotherapeutics Ltd. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 12 | 10 | −2 |
| Shares | 220.1K | 614.3K | +394.2K (+179.1%) |
| Value | $309.0K | $534.4K | +$225.4K (+73.0%) |
New holders (2)
Institutions that held Scinai Immunotherapeutics Ltd. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 362,448 | $315.3K | 0.01% |
| Qube Research & Technologies Ltd | 7 | $6 | 0.00% |
Sold out (4)
Institutions that held Scinai Immunotherapeutics Ltd. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Millennium Management LLC | 11,578 | $15.7K |
| Susquehanna International Group, LLP | 10,921 | $14.9K |
| Credit Agricole S A | 424 | $598 |
| NewSquare Capital LLC | 2 | $3 |